ArticleFrontiers in oncology2025
Case Report: Hypothalamic demyelinating lesion preceding lymphoma arising outside the central nervous system.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonneoplastic demyelinating brain lesions, known as sentinel lesions, occasionally precede primary central nervous system lymphomas (PCNSL). However, cerebral sentinel lesions associated with lymphoma "outside" the central nervous system (CNS) have not been reported. Here, we describe the case of a 76-year-old female who presented with rapidly progressive visual field disturbances. Magnetic resonance imaging revealed a hypothalamic lesion, and a biopsy demonstrated inflammatory demyelination with T-lymphocyte and macrophage infiltration, but no evidence of lymphoma. Steroid therapy was initiated only after biopsy. The lesions responded well to steroids and almost disappeared, and the patient was discharged with improvement in all symptoms except for diabetes insipidus. Three months later, the patient developed systemic symptoms, including osteolytic bone and skull lesions and multiple organ failure. A second biopsy of a skull lesion revealed diffuse large B-cell lymphoma (DLBCL), a non-germinal center B-cell-like subtype. Despite initiating chemotherapy, the patient died five months after the initial biopsy, although no recurrence of the brain lesion was observed. This case is the first to document a brain sentinel lesion preceding systemic DLBCL without associated cerebral lymphoma. It highlights the similarities with previously reported sentinel lesions in PCNSL, such as inflammatory demyelination and steroid responsiveness, while raising questions regarding the underlying mechanisms and challenges of early diagnosis. We emphasize the importance of considering sentinel lesions in patients with tumefactive inflammatory demyelination characterized by T-lymphocyte-dominant infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.